A phase I clinical trial of a new 5-valent rotavirus vaccine

► A new 5-valent rotavirus vaccine has been evaluated in a double-blind phase 1 trial. ► No severe adverse events were observed. ► There was no significant difference in the frequency of AE between vaccine and control groups. ► The proportion of seroconversion was larger in the vaccine group for all five serotypes. ► Antibody levels were significantly higher in the vaccine group in comparison to the placebo group.